Retatrutide vs Tirzepatide vs Semaglutide: Research Comparison

Overview

GLP-1 receptor agonists represent one of the most actively researched compound classes in metabolic science. Three compounds — semaglutide, tirzepatide, and retatrutide — differ fundamentally in their receptor targeting profile, creating distinct research contexts for each.

Receptor Targeting Comparison

Semaglutide

Mechanism: Selective GLP-1 receptor agonist

Structure: Modified GLP-1 analogue with fatty acid chain (C18 diacid)

Half-life: ~7 days (suitable for once-weekly dosing in clinical settings)

Semaglutide acts exclusively at GLP-1 receptors, stimulating insulin secretion, suppressing glucagon, and slowing gastric emptying. The single-receptor approach creates a well-characterised pharmacological profile.

Tirzepatide (Dual Agonist)

Mechanism: GLP-1/GIP dual receptor agonist

Structure: Novel synthetic peptide incorporating both GLP-1 and GIP activity

Half-life: ~5 days

Tirzepatide's additional GIP receptor activity produces additive effects compared to GLP-1 alone in research models. GIP signalling may enhance insulin sensitivity independently of GLP-1 pathways.

Retatrutide (Triple Agonist)

Mechanism: GLP-1/GIP/Glucagon triple receptor agonist

CAS: 2381089-83-2

Structure: LY3437943 — novel triagonist peptide

Retatrutide adds glucagon receptor agonism to the dual GLP-1/GIP profile. In preclinical models, glucagon receptor activation increases energy expenditure via hepatic gluconeogenesis and thermogenic pathways, potentially amplifying metabolic effects beyond dual agonism.

Research Context

Each compound offers distinct research utility:

• •Semaglutide — well-established single-receptor pharmacology; extensive clinical trial data
• •Tirzepatide — dual-pathway research with established GIP contribution data
• •Retatrutide — emerging triple-receptor research; novel glucagon component adds complexity

Available for Research

All three compound classes are available for in-vitro research from Peptide Warehouse Australia. View our Fat Loss category for current stock and COA data.

Disclaimer: All comparisons are based on published preclinical and clinical research literature. Information is for educational purposes only. Not medical advice.